RE:RE:RE:RE:RE:RE:RE:Rutherrinpatience69 wrote: I guess Marco what I am referring to or perhaps hoping for is that often times buy ins or buy outs can happen for a much higher price than the current market value. Once the market gets the sniff of a deal the price can catapult & then still sell for higher than share price so under those circumstances share price is less of a factor
Round and round we just keep saying the same thing for eternia.... 8 years talking about buyouts and market 'sniffing' and catapulting.
https://www.fiercebiotech.com/biotech/asco-novartis-backs-up-endocyte-buyout-prostate-cancer-data
Endocyte's first offer from Novartis was $12 then a 10 month negotiation was doubled to $24.. so really.. when do u think negotiations happen here... late 2021... going into 2022.. https://ei.marketwatch.com/Multimedia/2018/10/18/Photos/NS/MW-GS019_ECYTPN_20181018094301_NS.png?uuid=bb55f3f8-d2db-11e8-8256-ac162d7bc1f7
Did Theralase management take good advantage of the Fast Track Status?
-Rolling Review.... allows them to submit data and not wait for a 'whole package' to be done prior too.
-Partial submission of BTD? as we go since Feb 7th.. those results could of been sent into for BTD.. and as the 60 days transpire.. the frequent communication would allow for a more seemless process.
Or is management about to f*** shareholders again with the annual report update..
-GLP complete by Dr.Mandel.... Phase 1 GBM? since Tox was Q4 2021?
Who knows.. after 8 years. The AGM if allowed will not be pleasant at all if were anywhere near the high of 2019 .50c... at minimum needs to double that price